Fundamental Analysis of QUALIGEN THERAPEUTICS INC(NASDAQ:QLGN) stock

Fundamental Rating

Overall QLGN gets a fundamental rating of 0 out of 10. We evaluated QLGN against 588 industry peers in the Biotechnology industry. QLGN may be in some trouble as it scores bad on both profitability and health. QLGN does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year QLGN has reported negative net income.

QLGN had a negative operating cash flow in the past year.

In the past 5 years QLGN always reported negative net income.

QLGN had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

QLGN has a worse Return On Assets (-659.87%) than 98.80% of its industry peers.

		Industry Rank	Sector Rank
ROA	-659.87%
ROE	N/A
ROIC	N/A

ROA(3y)-278.65%

ROA(5y)-297.99%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for QLGN so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

QLGN does not have a ROIC to compare to the WACC, probably because it is not profitable.

QLGN has more shares outstanding than it did 1 year ago.

The number of shares outstanding for QLGN has been increased compared to 5 years ago.

Compared to 1 year ago, QLGN has a worse debt to assets ratio.

2.2 Solvency

QLGN has an Altman-Z score of -100.26. This is a bad value and indicates that QLGN is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -100.26, QLGN is doing worse than 96.06% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-100.26

ROIC/WACCN/A

WACC8.21%

2.3 Liquidity

QLGN has a Current Ratio of 0.28. This is a bad value and indicates that QLGN is not financially healthy enough and could expect problems in meeting its short term obligations.

QLGN's Current ratio of 0.28 is on the low side compared to the rest of the industry. QLGN is outperformed by 97.43% of its industry peers.

QLGN has a Quick Ratio of 0.28. This is a bad value and indicates that QLGN is not financially healthy enough and could expect problems in meeting its short term obligations.

QLGN has a worse Quick ratio (0.28) than 97.26% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.28
Quick Ratio	0.28

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 44.77% over the past year.

QLGN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -34.94%.

EPS 1Y (TTM)44.77%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q68.73%

Revenue 1Y (TTM)-34.94%

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2Q-100%

3.2 Future

QLGN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.80% yearly.

Based on estimates for the next years, QLGN will show a very negative growth in Revenue. The Revenue will decrease by -41.42% on average per year.

EPS Next Y62.96%

EPS Next 2Y31.8%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year-100%

Revenue Next 2Y-41.42%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for QLGN. In the last year negative earnings were reported.

Also next year QLGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as QLGN's earnings are expected to grow with 31.80% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y31.8%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

QLGN does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

QUALIGEN THERAPEUTICS INC

NASDAQ:QLGN (4/26/2024, 7:12:20 PM)

After market: 0.307 +0.02 (+5.68%)

0.2905

-0.01 (-2.19%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap1.83M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-659.87%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover1.59

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	0.28
Quick Ratio	0.28
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)44.77%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y62.96%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-34.94%

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

QUALIGEN THERAPEUTICS INC (QLGN)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens